Does first-line treatment impact the cost-effectiveness of second-line treatment for elderly metastatic colon cancer patients?

被引：0
|
作者：
Mullins, C. Daniel
Woldemichael, Andinet
Zheng, Zhiyuan
Onukwugha, Ebere
Seal, Brian S.
Hanna, Nader
机构：
[1] Univ Maryland, Sch Pharm, Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[3] Amer Canc Soc, Atlanta, GA 30329 USA
[4] Bayer HealthCare Pharmaceut, Wayne, NJ USA
[5] Univ Maryland, Dept Surg, Div Gen & Oncol Surg, Baltimore, MD 21201 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.585
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium
    Van, Nooten F.
    Dewilde, S.
    Van Belle, S.
    Marbaix, S.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A329 - A329
  • [22] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    El-Rayes, Bassel F.
    Flowers, Christopher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] THE COST-EFFECTIVENESS OF CATHETER ABLATION AS FIRST-LINE TREATMENT
    Aronsson, M.
    Walfridsson, H.
    Janzon, M.
    Walfridsson, U.
    Levin, L. A.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A529 - A529
  • [24] Cost-effectiveness of olanzapine as a first-line treatment: A comment
    Basu, Anirban
    [J]. VALUE IN HEALTH, 2006, 9 (05) : 357 - 357
  • [25] COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK
    Lam, Simon
    Barreto, Erin
    Scott, Rachael
    Kashani, Kianoush
    Khanna, Ashish
    Bauer, Seth
    [J]. CRITICAL CARE MEDICINE, 2020, 48
  • [26] Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia
    Mihajlovic, Jovan
    Pechlivanoglou, Petros
    Sabo, Ana
    Tomic, Zdenko
    Postma, Maarten J.
    [J]. CLINICAL THERAPEUTICS, 2013, 35 (12) : 1909 - 1922
  • [27] Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.
    Lauren, Brianna
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Ostvar, Sassan
    Laszkowska, Monika
    Chu, Jacqueline N.
    Manji, Gulam Abbas
    Neugut, Alfred I.
    Hur, Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Cost-effectiveness of second-line vasopressors for the treatment of septic shock
    Lam, Simon W.
    Barreto, Erin F.
    Scott, Rachael
    Kashani, Kianoush B.
    Khanna, Ashish K.
    Bauer, Seth R.
    [J]. JOURNAL OF CRITICAL CARE, 2020, 55 : 48 - 55
  • [29] Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer
    Levy-Piedbois, C
    Durand-Zaleski, I
    Juhel, H
    Schmitt, C
    Bellanger, A
    Piedbois, P
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (02) : 157 - 161
  • [30] Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
    Lauren, Brianna
    Ostvar, Sassan
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Laszkowska, Monika
    Chu, Jacqueline N.
    Hershman, Dawn L.
    Manji, Gulam
    Neugut, Alfred I.
    Hur, Chin
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
12345